Celltrion's COVID-19 Antibody Improves Outcomes in Phase 2 - COVID-19 Clinical Trial
Breaking News | COVID-19

Celltrion’s COVID-19 Antibody Improves Outcomes in Phase 2

Celltrion’s anti-SARS-CoV-2 antibody has improved outcomes in patients with mild to moderate COVID-19 in a phase 2/3 clinical trial. The Korean biopharma reported lower rates of progression to severe COVID-19, shortened time to clinical recovery and reduced viral load in patients on the drug.

Like anti-SARS-CoV-2 antibodies developed by Eli Lilly and Regeneron, Celltrion’s CT-P59 is designed to improve outcomes in COVID-19 patients by neutralizing the coronavirus. Building on preclinical evidence of efficacy, Celltrion moved CT-P59 into a phase 2/3 clinical trial in October. Top-line data from the 327 subjects enrolled in the first part of the study are now available.Investigators randomized participants to receive one of two doses of CT-P59, 40 mg/kg or 80 mg/kg, or placebo. The top-line data shared by Celltrion only cover the lower of the two doses of CT-P59.


Simulate Infections with a Medical Education Video Game

In the midst of the COVID-19 pandemic, Johnson & Johnson and Level Ex are helping support front-line healthcare workers with—wait for it—video games. Specifically, COVID-19 levels added to existing medical education video games. Armed with an educational grant from the Johnson & Johnson Institute aimed at addressing COVID-19 needs, medical education video game maker Level Ex built virus-specific levels for its Airway Ex, Pulm Ex and, most recently, Cardio Ex mobile games.

The new levels show pulmonologists, emergency medicine physicians, anesthesiologists and other healthcare professionals how to deal with the new challenges of COVID-19. “Since March, we’ve just been scrambling out diagnostic treatment decision-making content in those games and distributing it to our doctors, and now also making it available at our remote play platform,” Level Ex Founder and CEO Sam Glassenberg said.

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.